Meta tags:

Headings (most frequently used words):

ritlecitinib, contents, medical, uses, history, society, and, culture, references, further, reading, external, links, legal, status, economics,

Text of the page (most frequently used words):
the (35), #ritlecitinib (27), and (25), 2023 (25), interferon (17), from (14), retrieved (13), alopecia (13), litfulo (13), for (12), edit (12), inhibitors (11), with (10), 2024 (10), june (10), alfa (10), epoetin (10), areata (9), wikipedia (8), here (7), agonists (7), original (7), archived (7), participants (7), legal (6), was (6), receptor (6), kinase (6), acid (6), see (6), instead (6), trial (6), september (6), canada (6), this (5), use (5), page (5), july (5), articles (5), drug (5), drugs (5), status (5), pfizer (5), hair (5), other (5), interleukin (5), ifn (5), beta (5), erythropoietin (5), salt (5), contents (4), search (4), safety (4), loss (4), acetate (4), others (4), anti (4), factor (4), tofacitinib (4), peficitinib (4), antibodies (4), csf (4), treatment (4), clinical (4), links (4), april (4), severe (4), administration (4), medical (4), united (4), randomized (4), placebo (4), history (4), only (4), hide (4), move (4), sidebar (4), toggle (3), view (3), additional (3), non (3), source (3), chemical (3), short (3), description (3), wikidata (3), english (3), tyrosine (3), bromide (3), ruxolitinib (3), spironolactone (3), flutamide (3), cyproterone (3), bicalutamide (3), antiandrogens (3), finasteride (3), tacrolimus (3), pimecrolimus (3), lithium (3), tasocitinib (3), deuruxolitinib (3), baricitinib (3), tnf (3), gamma (3), colony (3), stimulating (3), fumarate (3), inhibitor (3), pmid (3), doi (3), article (3), which (3), october (3), union (3), information (3), european (3), august (3), health (3), approved (3), states (3), society (3), culture (3), were (3), once (3), daily (3), data (3), tools (3), main (3), languages (2), table (2), code (2), contact (2), about (2), privacy (2), policy (2), text (2), under (2), terms (2), may (2), using (2), attribution (2), license (2), 2026 (2), categories (2), containing (2), multiple (2), cas (2), chemicals (2), kegg (2), march (2), american (2), medicine (2), portal (2), oclacitinib (2), lebrikizumab (2), glycopyrronium (2), gluconate (2), potassium (2), abrocitinib (2), dutasteride (2), reductase (2), minoxidil (2), hydrocortisone (2), topical (2), corticosteroids (2), skin (2), urea (2), calcineurin (2), zinc (2), pyrithione (2), selenium (2), olamine (2), ciclopirox (2), lestaurtinib (2), cytokine (2), modulators (2), deucravacitinib (2), nsc (2), upadacitinib (2), filgotinib (2), jak (2), ifnlr (2), fontolizumab (2), emapalumab (2), faralimomab (2), anifrolumab (2), peginterferon (2), omega (2), kappa (2), alpha (2), thrombopoietin (2), macrophage (2), granulocyte (2), pegol (2), epo (2), hyaluronidase (2), unsorted (2), lymphocyte (2), globulin (2), aritox (2), spesolimab (2), sirukumab (2), siltuximab (2), satralizumab (2), sarilumab (2), risankizumab (2), olokizumab (2), ixekizumab (2), canakinumab (2), brodalumab (2), briakinumab (2), bimekizumab (2), daclizumab (2), basiliximab (2), tocilizumab (2), cd3 (2), target (2), secukinumab (2), anakinra (2), intracellular (2), gov (2), 06651600 (2), number (2), external (2), zhang (2), s2cid (2), 1016 (2), efficacy (2), adults (2), adolescents (2), double (2), blind (2), 2022 (2), scalp (2), further (2), reading (2), fda (2), food (2), trials (2), february (2), therapeutic (2), product (2), dailymed (2), november (2), decision (2), summary (2), tga (2), australia (2), references (2), economics (2), 718 (2), controlled (2), twelve (2), years (2), age (2), older (2), republic (2), uses (2), mouth (2), name (2), medication (2), key (2), inchi (2), chebi (2), names (2), appearance (2), upload (2), file (2), changes (2), read (2), log (2), create (2), account (2), donate (2), menu (2), add, topic, mobile, cookie, statement, statistics, developers, conduct, contacts, disclaimers, available, apply, site, you, agree, registered, trademark, profit, organization, wikimedia, foundation, inc, creative, commons, sharealike, rendered, parsoid, last, edited, utc, hidden, unverified, infoboxes, registry, numbers, indexlabels, infobox, without, standard, different, dmy, dates, all, written, matches, developed, piperidines, carboxamides, pyrrolopyrimidines, medications, https, org, index, php, title, oldid, 1364115761, tralokinumab, tiratricol, sofpironium, progesterone, progestogens, pregnenolone, povidone, iodine, oxymetazoline, nemolizumab, metandienone, magnesium, sulfate, lokivetmab, ivermectin, ilunocitinib, hydrogen, peroxide, hyaluronic, tosylate, estradiol, estrogens, dupilumab, diclofenac, deoxycholic, delgocitinib, cromoglicic, crisaborole, collagen, calcium, caffeine, brimonidine, benzoylperoxide, atinvicitinib, testosterone, androgens, aminobenzoate, eflornithine, growth, suvomipic, pp405, jxl069, nepidermin, channel, openers, topilutamide, fluridil, saw, palmetto, extract, alfatradiol, treatments, oxaceprol, gamolenic, alitretinoin, inflammatories, melanotan, afamelanotide, darkening, monobenzone, mequinol, hydroquinone, lightening, succinate, salts, cream, sulfur, salicylic, resorcinol, coal, tar, keratolytics, isotretinoin, cyclosporin, antihistamines, xenysalate, disulfide, sulfide, piroctone, miconazole, ketoconazole, clotrimazole, climbazole, cetrimide, cetrimonium, bifonazole, antifungals, seborrheics, preparations, d11, dermatological, sunitinib, sorafenib, quizartinib, midostaurin, emfilermin, thymic, stromal, lymphopoietin, tslp, oncostatin, osm, leukemia, leukocyte, inhibitory, lif, fms, like, ligand, flt3l, cardiotrophin, cytokines, tyk2, 449829, 39923, whi, 154, tcs, 21311, decernotinib, 509, cercosporamide, jak3, 1008, pacritinib, 33994, 7908, cyt387, cucurbitacin, elatericin, jsi, 124, chz868, azd, 1480, atiprimod, jak2, momelotinib, jak1, tgfβ, 28r, iii, ifngr, bifarcept, decoy, receptors, sifalimumab, rontalizumab, medi, 545, ifnw1, ifnk, ifnb3, ifnb1, alfacon, ifna21, ifna17, ifna16, ifna14, ifna13, ifna10, ifna8, ifna7, ifna6, ifna5, ifna4, ifna2, ifna1, albinterferon, ifnar, thpo, mgdf, lusutrombopag, avatrombopag, romiplostim, promegapoietin, pegacaristim, eltrombopag, scf, kit, agerafenib, mirimostim, lanimostim, cilmostim, csf1, otilimab, namilumab, mavrilimumab, sargramostim, regramostim, molgramostim, milodistim, ecogramostim, csf2, pegnartograstim, pegfilgrastim, nartograstim, lipegfilgrastim, leridistim, lenograstim, filgrastim, csf3, sihematide, 018b, peginesatide, methoxy, polyethylene, glycol, cera, mircera, zeta, theta, epsilon, delta, darbepoetin, cnto, 530, carbamylated, asialo, ara, 290, chemokine, tolebrutinib, tegomil, siponimod, remibrutinib, ponesimod, pirfenidone, pegcetacoplan, ozanimod, nerandomilast, iptacopan, imlifidase, fingolimod, etrasimod, efgartigimod, diroximel, dimethyl, difamilast, darvadstrocel, danicopan, cladribine, blisibimod, belumosudil, avacopan, atacicept, telitacicept, rilonacept, alefacept, aflibercept, opinercept, etanercept, belatacept, abatacept, ctla, cept, fusion, thymocyte, polyclonal, vepalimomab, vapaliximab, teprotumumab, telimomab, talizumab, sutimlimab, siplizumab, sibeprenlimab, seniprutug, rozanolixizumab, rovelizumab, reslizumab, pexelizumab, ofatumumab, nipocalimab, morolimumab, maslimomab, inebilizumab, divozilimab, crovalimab, cedelizumab, begelomab, batoclimab, atorolimumab, alemtuzumab, zolimomab, inolimomab, cd25, odulimomab, lfa, vedolizumab, natalizumab, integrin, metelimumab, lerdelimumab, bertilimumab, cat, belimumab, blys, ruplizumab, frexalimab, cd154, gavilimomab, cd147, basigin, galiximab, cd80, aselizumab, cd62l, selectin, toralizumab, teneliximab, cd40, lumiliximab, gomiliximab, cd23, ublituximab, rituximab, pascolizumab, ocrelizumab, obinutuzumab, cd20, erlizumab, cd18, efalizumab, cd11a, zanolimumab, keliximab, clenoliximab, cd4, visilizumab, teplizumab, otelixizumab, muromonab, cellular, 17a, ustekinumab, tildrakizumab, guselkumab, elsilimomab, omalizumab, immunoglobulin, mepolizumab, netakimab, nerelimomab, infliximab, golimumab, certolizumab, afelimomab, adalimumab, ravulizumab, eculizumab, complement, component, serum, noncellular, monoclonal, extracellular, zotarolimus, umirolimus, temsirolimus, sirolimus, ridaforolimus, everolimus, mtor, antagonists, reception, itacitinib, apremilast, pde4, thalidomide, pomalidomide, lenalidomide, imids, gusperimus, abetimus, voclosporin, ciclosporin, cyclophilin, fkbp, macrolides, methotrexate, antifolate, teriflunomide, leflunomide, dihydroorotate, dehydrogenase, mycophenolic, azathioprine, purine, synthesis, antimetabolites, initiation, l04, immunosuppressants, immunosuppressive, clinicaltrials, allegro, nct03732807, king, harcha, szepietowski, shapiro, lynde, 10387, london, england, 1529, 258114404, 37062298, s0140, 6736, 00222, 1518, 401, lancet, randomised, multicentre, phase, guttman, yassky, pavel, diaz, del, duca, estrada, 1328, 244824663, 34863853, jaci, 2021, 036, 1318, 149, journal, allergy, immunology, brepocitinib, demonstrate, significant, improvement, biomarkers, kansteiner, fierce, pharma, enters, scene, adolescent, nod, rival, lilly, olumiant, press, release, via, business, wire, approves, public, domain, incorporates, snapshots, ramírez, marín, tosti, 374, 35210753, 8860347, pmc, 2147, dddt, s334727, 363, design, development, therapy, evaluating, potential, inxight, register, medicinal, products, medicines, agency, epar, national, library, capsule, regulatory, basis, pty, ltd, goods, annual, list, price, 000, based, evidence, evaluated, including, totalis, universalis, 130, 131, 457, dosing, regimens, evaluation, also, supported, two, 200, four, weeks, followed, conducted, 128, sites, countries, argentina, chile, china, colombia, czech, germany, hungary, japan, korea, mexico, poland, russian, federation, spain, taiwan, kingdom, individuals, indicated, most, common, side, effects, include, headache, diarrhea, acne, rashes, eczema, fever, ulcers, dizziness, shingles, rash, abnormal, findings, some, laboratory, test, results, sold, brand, used, inhibits, janus, yozlvafwylsrrn, vzxypilpsa, cbrjpfgixufmtm, wdereuqcsa, c15h19n5o, 11h, 8h2, 2h3, t10, n1c, nc2ncnc3, ccc23, smiles, interactive, image, model, jsmol, mol, 285, 351, molar, mass, formula, physical, chembl4085457, chembl, 229233, d11970, eag4t1459k, 2oye00pc25, unii, 81368003, 59718512, chemspider, dbsalt003482, db14924, drugbank, 9559, iuphar, bps, 118115473, cid, pubchem, 2192215, 1792180, methyl, pyrrolo, pyrimidin, amino, piperidin, prop, one, iupac, identifiers, prescription, who, l04af08, atc, routes, pregnancy, category, a624015, medlineplus, monograph, com, ahfs, trade, pharmaceutical, compound, treat, free, encyclopedia, item, projects, printable, version, download, pdf, print, export, switch, legacy, parser, get, shortened, url, cite, permanent, link, related, what, general, actions, talk, română, italiano, עברית, subsection, top, personal, special, pages, recent, community, learn, help, contribute, random, current, events, navigation, jump, content,

Text of the page (random words):
anges upload file special pages search search appearance donate create account log in personal tools donate create account log in contents move to sidebar hide top 1 medical uses 2 history 3 society and culture toggle society and culture subsection 3 1 legal status 3 2 economics 4 references 5 further reading 6 external links toggle the table of contents ritlecitinib 4 languages עברית italiano română 中文 edit links article talk english read edit view history tools tools move to sidebar hide actions read edit view history general what links here related changes upload file permanent link page information cite this page get shortened url switch to legacy parser print export download as pdf printable version in other projects wikidata item appearance move to sidebar hide from wikipedia the free encyclopedia medication to treat hair loss pharmaceutical compound ritlecitinib clinical data trade names litfulo other names pf 06651600 ahfs drugs com monograph medlineplus a624015 license data us dailymed ritlecitinib pregnancy category au d 1 routes of administration by mouth atc code l04af08 who legal status legal status au s4 prescription only 2 1 ca only 3 4 5 us only 6 eu rx only 7 8 identifiers iupac name 1 2 s 5 r 2 methyl 5 7 h pyrrolo 2 3 d pyrimidin 4 yl amino piperidin 1 yl prop 2 en 1 one cas number 1792180 81 4 as salt 2192215 81 7 pubchem cid 118115473 iuphar bps 9559 drugbank db14924 as salt dbsalt003482 chemspider 59718512 as salt 81368003 unii 2oye00pc25 as salt eag4t1459k kegg as salt d11970 chebi chebi 229233 chembl chembl4085457 chemical and physical data formula c 15 h 19 n 5 o molar mass 285 351 g mol 1 3d model jsmol interactive image smiles c cc o n1c c h nc2ncnc3 nh ccc23 cc c h 1c inchi inchi 1s c15h19n5o c1 3 13 21 20 8 11 5 4 10 20 2 19 15 12 6 7 16 14 12 17 9 18 15 h3 6 7 9 11h 1 4 5 8h2 2h3 h2 16 17 18 19 t10 11 m0 s1 key cbrjpfgixufmtm wdereuqcsa n key yozlvafwylsrrn vzxypilpsa n ritlecitinib sold under the brand name litfulo is a medication used for the treatment of severe alopecia areata hair loss 6 ritlecitinib is a kinase inhibitor which inhibits janus kinase 3 and tyrosine kinase 6 9 10 the most common side effects include headache diarrhea acne rashes eczema fever mouth ulcers dizziness shingles rash and abnormal findings in some laboratory test results 11 ritlecitinib was approved for medical use in the united states in june 2023 6 11 12 in the european union in september 2023 7 and in canada in november 2023 4 medical uses edit ritlecitinib is indicated for the treatment of severe alopecia areata for individuals twelve years of age and older 6 7 history edit the us food and drug administration fda approved ritlecitinib based on evidence from a clinical trial of 718 participants with severe alopecia areata 11 the efficacy and safety of ritlecitinib were evaluated in a randomized double blind placebo controlled trial in 718 participants twelve years of age and older with alopecia areata with 50 scalp hair loss including alopecia totalis and alopecia universalis 11 the trial randomized 130 participants to ritlecitinib 50 mg once daily 131 participants to placebo and 457 participants to other ritlecitinib dosing regimens 11 the safety evaluation was also supported by two placebo controlled trials in which 80 participants were randomized to ritlecitinib 200 mg once daily for four weeks followed by 50 mg once daily and 82 participants were randomized to placebo 11 the trial was conducted at 128 sites in 18 countries in argentina australia canada chile china colombia czech republic germany hungary japan republic of korea mexico poland russian federation spain taiwan the united kingdom and the united states 11 society and culture edit legal status edit in 2023 ritlecitinib was approved for medical use in the united states 6 11 in the european union 7 and in canada 4 economics edit the annual list price of ritlecitinib is us 49 000 13 references edit 1 2 litfulo ritlecitinib therapeutic goods administration tga 30 july 2024 retrieved 12 october 2024 litfulo pfizer australia pty ltd tga gov au retrieved 14 july 2026 litfulo product information health canada 13 february 2024 retrieved 3 march 2024 1 2 3 summary basis of decision for litfulo health canada 18 july 2024 retrieved 28 august 2024 regulatory decision summary for litfulo health canada 29 november 2023 retrieved 2 april 2024 1 2 3 4 5 6 litfulo ritlecitinib capsule dailymed u s national library of medicine 23 june 2023 archived from the original on 29 august 2023 retrieved 28 august 2023 1 2 3 4 litfulo epar european medicines agency 18 september 2023 archived from the original on 19 september 2023 retrieved 20 september 2023 litfulo product information union register of medicinal products 18 september 2023 archived from the original on 1 october 2023 retrieved 1 october 2023 ritlecitinib inxight drugs archived from the original on 25 june 2023 retrieved 24 june 2023 ramírez marín ha tosti a february 2022 evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata drug design development and therapy 16 363 374 doi 10 2147 dddt s334727 pmc 8860347 pmid 35210753 1 2 3 4 5 6 7 8 drug trials snapshots litfulo u s food and drug administration 23 june 2023 archived from the original on 5 april 2024 retrieved 29 april 2024 this article incorporates text from this source which is in the public domain fda approves pfizer s litfulo ritlecitinib for adults and adolescents with severe alopecia areata press release pfizer 23 june 2023 archived from the original on 25 june 2023 retrieved 24 june 2023 via business wire kansteiner f 26 june 2023 pfizer s litfulo enters the scene in alopecia with adolescent nod to rival lilly s olumiant fierce pharma archived from the original on 8 july 2023 retrieved 18 september 2023 further reading edit guttman yassky e pavel ab diaz a zhang n del duca e estrada y et al april 2022 ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers the journal of allergy and clinical immunology 149 4 1318 1328 doi 10 1016 j jaci 2021 10 036 pmid 34863853 s2cid 244824663 king b zhang x harcha wg szepietowski jc shapiro j lynde c et al may 2023 efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata a randomised double blind multicentre phase 2b 3 trial lancet 401 10387 london england 1518 1529 doi 10 1016 s0140 6736 23 00222 2 pmid 37062298 s2cid 258114404 external links edit clinical trial number nct03732807 for pf 06651600 for the treatment of alopecia areata allegro 2b 3 at clinicaltrials gov v t e immunosuppressive drugs immunosuppressants l04 intracellular initiation antimetabolites purine synthesis inhibitors azathioprine mycophenolic acid dihydroorotate dehydrogenase inhibitors leflunomide teriflunomide antifolate methotrexate macrolides other il 2 inhibitors fkbp cyclophilin calcineurin ciclosporin pimecrolimus tacrolimus voclosporin abetimus gusperimus imids lenalidomide pomalidomide thalidomide pde4 inhibitor apremilast jak inhibitors baricitinib deucravacitinib deuruxolitinib filgotinib itacitinib peficitinib ritlecitinib tofacitinib upadacitinib intracellular reception il 1 receptor antagonists anakinra mtor everolimus ridaforolimus sirolimus temsirolimus umirolimus zotarolimus extracellular antibodies monoclonal serum target noncellular complement component 5 eculizumab ravulizumab tnf adalimumab afelimomab certolizumab pegol golimumab infliximab nerelimomab interleukin anakinra basiliximab bimekizumab briakinumab brodalumab canakinumab daclizumab netakimab olokizumab sarilumab satralizumab secukinumab siltuximab sirukumab spesolimab tocilizumab interleukin 5 mepolizumab immunoglobulin e omalizumab interferon faralimomab il 6 elsilimomab il 12 il 13 and il 23 guselkumab lebrikizumab risankizumab tildrakizumab ustekinumab il 17a ixekizumab secukinumab cellular target cd3 muromonab cd3 otelixizumab teplizumab visilizumab cd4 clenoliximab keliximab zanolimumab cd11a efalizumab cd18 erlizumab cd20 obinutuzumab ocrelizumab hyaluronidase pascolizumab rituximab ublituximab cd23 gomiliximab lumiliximab cd40 teneliximab toralizumab cd62l l selectin aselizumab cd80 galiximab cd147 basigin gavilimomab cd154 frexalimab ruplizumab blys belimumab cat bertilimumab lerdelimumab metelimumab integrin natalizumab vedolizumab interleukin 6 receptor tocilizumab lfa 1 odulimomab il 2 receptor cd25 basiliximab daclizumab inolimomab t lymphocyte zolimomab aritox unsorted alemtuzumab anifrolumab atorolimumab batoclimab begelomab bimekizumab briakinumab brodalumab canakinumab cedelizumab crovalimab divozilimab emapalumab fontolizumab inebilizumab ixekizumab maslimomab morolimumab nipocalimab ofatumumab olokizumab pexelizumab reslizumab risankizumab rovelizumab rozanolixizumab sarilumab satralizumab seniprutug sibeprenlimab siltuximab siplizumab sirukumab spesolimab sutimlimab talizumab telimomab aritox teprotumumab vapaliximab vepalimomab polyclonal anti thymocyte globulin anti lymphocyte globulin cept fusion ctla 4 abatacept belatacept tnf inhibitor etanercept opinercept aflibercept alefacept rilonacept telitacicept unsorted atacicept avacopan belumosudil blisibimod cladribine danicopan darvadstrocel difamilast dimethyl fumarate diroximel fumarate efgartigimod alfa hyaluronidase etrasimod fingolimod imlifidase iptacopan nerandomilast ozanimod pegcetacoplan pirfenidone ponesimod remibrutinib siponimod tegomil fumarate tolebrutinib v t e cytokine receptor modulators chemokine see here instead csf erythropoietin agonists ara 290 asialo erythropoietin carbamylated erythropoietin cnto 530 darbepoetin alfa epoetin alfa epoetin beta epoetin delta epoetin epsilon epoetin gamma epoetin kappa epoetin omega epoetin theta epoetin zeta erythropoietin epo erythropoietin fc methoxy polyethylene glycol epoetin beta cera mircera peginesatide pegol sihematide epo 018b g csf csf3 agonists filgrastim granulocyte colony stimulating factor lenograstim leridistim lipegfilgrastim nartograstim pegfilgrastim pegnartograstim gm csf csf2 agonists ecogramostim granulocyte macrophage colony stimulating factor milodistim molgramostim regramostim sargramostim antibodies mavrilimumab namilumab otilimab m csf csf1 agonists cilmostim interleukin 34 lanimostim macrophage colony stimulating factor mirimostim kinase inhibitors agerafenib scf c kit see here instead thrombopoietin agonists eltrombopag pegacaristim promegapoietin romiplostim avatrombopag lusutrombopag thrombopoietin thpo mgdf interferon ifnar α β i agonists albinterferon interferon alpha interferon alfa ifn α interferon alfa ifna1 ifna2 ifna4 ifna5 ifna6 ifna7 ifna8 ifna10 ifna13 ifna14 ifna16 ifna17 ifna21 interferon alfa 2a interferon alfa 2b interferon alfa n1 interferon alfacon 1 interferon alpha n3 interferon beta ifn β ifnb1 ifnb3 interferon beta 1a interferon beta 1b interferon kappa ifn ε κ τ ζ ifnk interferon omega ifn ω ifnw1 peginterferon alfa 2a peginterferon alfa 2b antibodies anifrolumab faralimomab medi 545 rontalizumab sifalimumab decoy receptors bifarcept ifngr γ ii agonists interferon gamma ifn γ interferon gamma 1b antibodies emapalumab fontolizumab ifnlr λ iii see il 28r ifnlr here instead interleukin see here instead tgfβ see here instead tnf see here instead others jak inhibitors jak1 abrocitinib baricitinib deuruxolitinib filgotinib momelotinib oclacitinib peficitinib ruxolitinib tofacitinib tasocitinib upadacitinib jak2 atiprimod azd 1480 baricitinib chz868 cucurbitacin i elatericin b jsi 124 cyt387 deuruxolitinib lestaurtinib nsc 7908 nsc 33994 pacritinib peficitinib ruxolitinib sd 1008 tofacitinib tasocitinib jak3 cercosporamide decernotinib vx 509 peficitinib ritlecitinib tcs 21311 tofacitinib tasocitinib whi p 154 zm 39923 zm 449829 tyk2 deucravacitinib others additional cytokines cardiotrophin 1 ct 1 fms like tyrosine kinase 3 ligand flt3l leukemia leukocyte inhibitory factor lif oncostatin m osm thymic stromal lymphopoietin tslp additional cytokine receptor modulators emfilermin lestaurtinib midostaurin quizartinib sorafenib sunitinib v t e other dermatological preparations d11 anti seborrheics antiandrogens bicalutamide cyproterone acetate flutamide spironolactone antifungals bifonazole cetrimonium bromide cetrimide ciclopirox olamine ciclopirox climbazole clotrimazole ketoconazole miconazole piroctone olamine selenium disulfide selenium sulfide xenysalate zinc pyrithione pyrithione zinc antihistamines calcineurin inhibitors cyclosporin pimecrolimus tacrolimus isotretinoin keratolytics coal tar resorcinol salicylic acid sulfur urea urea containing cream lithium salts lithium gluconate lithium succinate topical corticosteroids e g hydrocortisone skin lightening hydroquinone mequinol monobenzone skin darkening afamelanotide melanotan ii anti inflammatories alitretinoin gamolenic acid oxaceprol pimecrolimus tacrolimus topical corticosteroids e g hydrocortisone alopecia treatments 5α reductase inhibitors alfatradiol dutasteride finasteride saw palmetto extract antiandrogens bicalutamide cyproterone acetate flutamide spironolactone topilutamide fluridil potassium channel openers minoxidil others minoxidil finasteride nepidermin ritlecitinib suvomipic pp405 jxl069 hair growth inhibitors 5α reductase inhibitors dutasteride finasteride antiandrogens bicalutamide cyproterone acetate flutamide spironolactone eflornithine others abrocitinib aminobenzoate potassium androgens e g testosterone atinvicitinib benzoylperoxide brimonidine caffeine calcium gluconate collagen crisaborole cromoglicic acid delgocitinib deoxycholic acid diclofenac dupilumab estrogens e g estradiol glycopyrronium bromide glycopyrronium tosylate hyaluronic acid hydrogen peroxide ilunocitinib ivermectin lebrikizumab lokivetmab magnesium sulfate metandienone nemolizumab oclacitinib oxymetazoline povidone iodine pregnenolone acetate progestogens e g progesterone ruxolitinib sofpironium bromide tiratricol tralokinumab portal medicine retrieved from https en wikipedia org w index php title ritlecitinib oldid 1364115761 categories hair loss medications non receptor tyrosine kinase inhibitors pyrrolopyrimidines carboxamides piperidines drugs developed by pfizer hidden categories articles with short description short description matches wikidata use american english from june 2023 all wikipedia articles written in american english use dmy dates from march 2024 short description is different from wikidata drugs with non standard legal status articles without kegg source multiple chemicals in infobox drug chemicals using indexlabels chemical articles with multiple cas registry numbers articles containing unverified chemical infoboxes source attribution this page was last edited on 14 july 2026 at 16 09 utc page was rendered with parsoid text is available under the creative commons attribution sharealike 4 0 license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia is a registered ...